A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...
Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has progressed after chemotherapy and immunotherapy.
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...
For years, scientists have viewed cancer as a localized glitch in which cells refuse to stop dividing. Scientists have long ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...
When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer ...
Study Highlights the Efficacy of PMC in Suppressing Non-Small Cell Lung Cancer Growth SEOUL, SOUTH KOREA, January 23, 2026 ...
About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...
Sabari — editor-in-chief of CURE, assistant professor at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at Perlmutter Cancer Center — discussed how various ...